Iron nanomedicines induce Toll-like receptor activation, cytokine production and complement activation

Biomaterials

Volumn 119, Issue , 2017, Pages 68-77

  Verhoef, Johan J F ^a   de Groot, A Marit ^b   van Moorsel, Marc ^a   Ritsema, Jeffrey ^a   Beztsinna, Nataliia ^a   Maas, Coen ^c   Schellekens, Huub ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Complement activation; Cytokines; Hypersensitivity like reactions; Innate immune system; Iron nanomedicines; Toll like receptors

Indexed keywords

BLOOD; CHEMICAL ACTIVATION; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; IMMUNE SYSTEM; INTERFERONS; IRON; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

COMPLEMENT ACTIVATIONS; CYTOKINES; HYPERSENSITIVITY-LIKE REACTIONS; INNATE IMMUNE SYSTEMS; TOLL-LIKE RECEPTORS;

IRON COMPOUNDS;

CHOLESTEROL; FERRIC CARBOXYMALTOSE; FERRIC GLUCONATE; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON; IRON ISOMALTOSIDE; IRON SACCHARATE; METHYL BETA CYCLODEXTRIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE; METAL NANOPARTICLE;

ALLERGIC REACTION; ARTICLE; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG FORMULATION; HUMAN; IN VITRO STUDY; INNATE IMMUNITY; NANOMEDICINE; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SCANNING TRANSMISSION ELECTRON MICROSCOPY; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; IMMUNOLOGY; MONONUCLEAR CELL; UPREGULATION;

CELLS, CULTURED; COMPLEMENT ACTIVATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; INFLAMMATION MEDIATORS; IRON; LEUKOCYTES, MONONUCLEAR; METAL NANOPARTICLES; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 85006298208     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.11.025     Document Type: Article

References (35)

1. [1] Gasche, C., Lomer, M.C.E., Cavill, I., Weiss, G., Iron, anaemia, and inflammatory bowel diseases. Gut 53:8 (Aug. 2004), 1190–1197.
2. [2] Umbreit, J., Iron deficiency: a concise review. Am. J. Hematol. 78:3 (Mar. 2005), 225–231.
3. [3] Auerbach, M., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in Cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 22:7 (Apr. 2004), 1301–1307.
4. [4] Geisser, P., Burckhardt, S., The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 3:1 (2011), 12–33.
5. [5] Auerbach, M., Ballard, H., Clinical use of intravenous iron: administration, efficacy, and safety. Hematol. Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. Educ. Program 2010 (2010), 338–347.
6. [6] Danielson, B.G., Structure, chemistry, and pharmacokinetics of intravenous iron agents. J. Am. Soc. Nephrol. JASN 15:Suppl 2 (Dec. 2004), S93–S98.
7. [7] Bailie, G.R., Verhoef, J.-J., Differences in the reporting rates of serious allergic adverse events from intravenous iron by country and population. Clin. Adv. Hematol. Oncol. HO 10:2 (Feb. 2012), 101–108.
8. [8] Rampton, D., et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 99:11 (Nov. 2014), 1671–1676.
9. [9] Wang, C., et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 314:19 (Nov. 2015), 2062–2068.
10. [10] Bircher, A.J., Auerbach, M., Hypersensitivity from intravenous iron products. Immunol. Allergy Clin. North Am. 34:3 (Aug. 2014), 707–723 x–xi.
11. [11] Szebeni, J., et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br. J. Pharmacol. 172:21 (Nov. 2015), 5025–5036.
12. [12] European Medicines Agency, New Recommendations to Manage Risk of Allergic Reactions with Intravenous Iron-containing Medicines. 2013 [Online]. Available http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500151308.pdf.
13. [13] Cançado, R.D., Muñoz, M., Intravenous iron therapy: how far have we come?. Rev. Bras. Hematol. E Hemoter. 33:6 (2011), 461–469.
14. [14] Novey, H.S., Pahl, M., Haydik, I., Vaziri, N.D., Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann. Allergy 72:3 (Mar. 1994), 224–228.
15. [15] Pai, A.B., Conner, T., McQuade, C.R., Olp, J., Hicks, P., Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biomet. Int. J. Role Met. Ions Biol. Biochem. Med. 24:4 (Aug. 2011), 603–613.
16. [16] Fell, L.H., Zawada, A.M., Rogacev, K.S., Seiler, S., Fliser, D., Heine, G.H., Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol. Dial. Transpl. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 29:4 (Apr. 2014), 809–822.
17. [17] Ma, Y., Abbate, V., Hider, R.C., Iron-sensitive fluorescent probes: monitoring intracellular iron pools. Metallomics 7:2 (Feb. 2015), 212–222.
18. [18] Takeuchi, O., Akira, S., Pattern recognition receptors and inflammation. Cell 140:6 (Mar. 2010), 805–820.
19. [19] Szebeni, J., Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216:2–3 (Dec. 2005), 106–121.
20. [20] Banda, N.K., et al. Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum. Part. Fibre Toxicol., 11, 2014, 64.
21. [21] Fine, D.P., Marney, S.R., Colley, D.G., Sergent, J.S., Des Prez, R.M., C3 shunt activation in human serum chelated with EGTA. J. Immunol. Balt. Md 1950 109:4 (Oct. 1972), 807–809.
22. [22] Hamad, I., Hunter, A.C., Szebeni, J., Moghimi, S.M., Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46:2 (Dec. 2008), 225–232.
23. [23] Gupta, A., Zhuo, J., Zha, J., Reddy, S., Olp, J., Pai, A., Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol., 11, 2010, 16.
24. [24] Li, H., Willingham, S.B., Ting, J.P.-Y., Re, F., Cutting edge: inflammasome activation by alum and Alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181:1 (Jul. 2008), 17–21.
25. [25] Pai, A.B., Boyd, A.V., McQuade, C.R., Harford, A., Norenberg, J.P., Zager, P.G., Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacother. J. Hum. Pharmacol. Drug Ther. 27:3 (Mar. 2007), 343–350.
26. ®)—development rationale and clinical experience. NDT Plus 4:Suppl 1 (Jun. 2011), i10–i13.
27. [27] Owens, D.E., Peppas, N.A., Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307:1 (Jan. 2006), 93–102.
28. [28] Carrstensen, H., Müller, R.H., Müller, B.W., Particle size, surface hydrophobicity and interaction with serum of parenteral fat emulsions and model drug carriers as parameters related to RES uptake. Clin. Nutr. Edinb. Scotl. 11:5 (Oct. 1992), 289–297.
29. [29] Aggarwal, P., Hall, J.B., McLeland, C.B., Dobrovolskaia, M.A., McNeil, S.E., Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61:6 (Jun. 2009), 428–437.
30. [30] Szebeni, J., Bedőcs, P., Csukás, D., Rosivall, L., Bünger, R., Urbanics, R., A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv. Drug Deliv. Rev. 64:15 (Dec. 2012), 1706–1716.
31. [31] Eisenbarth, S.C., Colegio, O.R., O'Connor, W., Sutterwala, F.S., Flavell, R.A., Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:7198 (Jun. 2008), 1122–1126.
32. [32] Luo, Y.-H., Chang, L.W., Lin, P., Metal-based nanoparticles and the immune system: activation, inflammation, and potential applications. Biomed. Res. Int., 2015, 2015, 143720.
33. [33] Wu, Y., et al. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy. Int. J. Pharm. 505:1–2 (May 2016), 167–174.
34. ®), a new intravenous iron preparation and its clinical implications. Eur. J. Pharm. Biopharm. 78:3 (Aug. 2011), 480–491.
35. [35] Shah, R.B., Yang, Y., Khan, M.A., Raw, A., Yu, L.X., Faustino, P.J., Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose. Int. J. Pharm. 464:1–2 (Apr. 2014), 46–52.